que la mortalidad a largo plazo esté relacionada sobre todo con la recidiva de la enfermedad actuaciones en una guía de seguimiento del paciente trasplantado. . documento recoge recomendaciones farmacoterapéuticas, de autocuidado, de . de las guías. • Algunos pacientes pueden comenzar con una diabetes de. Efectividad del seguimiento farmacoterapéutico en diabéticos tipo 2 clínica, se obtuvo información sobre medicamentos antidiabéticos utilizados, dosis, .. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Objetivos: Realizar un seguimiento farmacoterapéutico y educar a pacientes conocimiento sobre la menopausia y la THR en pacientes menopaúsicas. Keywords: Hormone . ministerial que generará Guías Clínicas y tratará . stock de éste por el laboratorio que los produce. Diabetes. 38%. Depresión.
|Published (Last):||21 October 2014|
|PDF File Size:||1.68 Mb|
|ePub File Size:||13.7 Mb|
|Price:||Free* [*Free Regsitration Required]|
There were no cases of Quantitative Insecurity. Cost of diabetes mellitus in Spain.
During the initial and final visits for the intervention group, the intervention was accepted and the health problem was solved in 72 cases DM affects million individuals around the world, million are in America, and nearly million are in Latin America and the Caribbean.
The NOMs with the highest prevalence were those for Non-Quantitative Insecurity; therefore, these represent a highly prevalent problem.
The sample was formed by 18 to 90 year old patients diabees CKD diagnosis, on polymedication, defined as patients under pharmacological treatment with over 5 medications 20hospitalized and also outpatients, managed during nine months. A descriptive analysis was conducted with central tendency and dispersion measures for quantitative variables, and relative frequencies for qualitative variables.
On the other hand, there was an farmacorerapeutico in the haemoglobin levels in the optimal group. Therefore, it is necessary to involve all healthcare professionals and patients, in order to obtain as a result a better use of medications, to prevent NOMs, and to reduce the morbidity associated with drug therapy.
Universidad de Granada Grupo de Investigación en Atención Farmacéutica
Fifty-one 51 negative outcomes associated with medication were detected during the study; of these, Necessity NOMs, when patients are not receiving an adequate treatment for their condition, and the other cause is that the health problems of patients are not receiving treatment; Effectiveness NOMs, when the treatment does not meet the therapeutical objectives, based on the dose administered; and Safety NOMs, identified when health problems develop as a consequence of drug therapy, which can be dose-dependent or not.
On the other hand, hypertension and DM are the most important risk factors that lead to deterioration in renal function, because the kidney is one of the target organs in these conditions; at the same time, together they will increase the cardiovascular risk 22 Dose readjustments were conducted because treatments were not effective and safe, through pharmaceutical intervention.
In nephropathy cases with hypoalbuminemia, drug effects of higher intensity can develop as a consequence of a reduced binding to plasma proteins and the subsequent increase in the free circulating fraction of the drug. We were able to identify in the patients in the study another less prevalent health problems. The descriptive analysis revealed the following: Rev Asoc Latinoam Diabetes.
Universidad de Granada Grupo de Investigación en Atención Farmacéutica [WorldCat Identities]
It was Descriptive, because the characteristics of the variables associated with the Diabrtes process were determined in patients segkimiento CKD, through the detection, fiabetes and solution of DRPs and NOMs and pharmaceutical interventions; and regarding time, it was Retrospective. Pharmacotherapeutic records were the primary source of information and the secondary sources were the clinical histories, the status guiia the condition, records of medications dispensed by quantities and costs, along with the data base from the EPS services with the records of services rendered to their users, appointments with their treating physicians, authorizations for paraclinical exams requested by the physicians, among others.
Patients were handed an Informed Consent for accepting or not. Of these 6 non-accepted interventions, 3 health problems were not solved, 12 dose readjustments were conducted, with cefepime as the drug with the highest number of dose seguimiennto most patients were in Stage III and V of CKD, and its main cause was hypertension and Diabetes Mellitus II.
In the future, in case pharmacotherapeutic monitoring is incorporated to daily care of diabetic patients, commitment is needed from healthcare insurance carriers EPS to make available the offices for the interviews, facilitate easier access to clinical records and paraclinical exams, updates of member addresses, generation of settings for meetings and discussion with treating physicians to socialize the NOM findings and the pharmaceutical recommendations, implement recommendations, and evaluate results.
Besides, in our study, there were more reports for Quantitative Ineffectiveness; the reason for this was the lack of modification in treatment dosing, even when this was allowed by the therapeutic window of drugs.
Safety was the NOM with the highest number of reports in terms of Non-Quantitative Insecurity, which means that in this case, dosing was not a factor triggering this NOM. The economic analysis between conducting interventions or keeping patients under habitual control, suggests to healthcare insurance carriers that implementing pharmacotherapeutic monitoring programs in patients with type-2 diabetes, may generate savings in costs related to caring for these patients.
Like a snake in the grass. Additionally, we conducted an analysis of the increasing cost-effectiveness ratios for each EPS. The researchers could not guarantee that the written reports with the intervention recommendations made by a pharmacist reached the treating physician; thus, the suggested intervention would or would not be accepted upon the detection of an NOM.
Seguimiento farmacoterapéutico en pacientes con insuficiencia renal crónica
Patients with type-2 diabetes mellitus, affiliated to the contributive regime of two EPS, who had continuity in antidiabetic treatment in the three months prior, defined by attendance to medical control and request for dispensing of normoglycemiant medication; these patients were over 18 years of age and accepted to participate in the study. Along with other studies, during the initial interview, we found co-morbidities frequently associated to diabetes, such as hypertension Patients changing EPS during the study; those whose physical or mental state did not permit communicating with the interviewer; and patients who did not remain in the city selected for the study during the time it took to develop such.
Hepler C, Strand L. El cociente medio del costo por paciente en el grupo control fue 1. This highlights the importance of this public health problem and its major clinical, social and economic impact, associated with Chronic Kidney Disease; therefore, it is necessary to involve all health professionals and patients, to obtain as a result a better use of medications, the prevention of NOMs and a reduction in morbidity associated with pharmacotherapy.
The most frequently identified co-medication corresponded to antihypertensive, hypolipidemic, thryroid hormone, antiplatelet drugs, among others. The primary etiology in all CKD patients appears in Figure 1.
In Colombia sufficient evaluations have not been conducted on the results of pharmaceutical care. Phone calls and visits were also made every four months to inquire about hospitalizations, visits to the general physician, specialist, and emergency services. Statistical Analysis The outcomes of the pharmaceutical interventions in the study were statistically analyzed with the STATA program version The variables were classified as dependent: